Results 31 to 40 of about 10,701 (213)
Oregon Psilocybin Advisory Board rapid evidence review and recommendations
, 2021 authors: the Oregon Psilocybin Evidence Review Writing Group, Atheir I. Abbas, MD, PhD, Angela Carter, ND, Thomas Jeanne, MD, MPH, Rachel Knox, MD, MBA, P.
core
De Novo Biosynthesis of Antidepressant Psilocybin in Escherichia coli
Microbial BiotechnologyPsilocybin, a tryptamine‐derived alkaloid, has been granted Breakthrough Therapy designation by the U.S. FDA for treatment‐resistant depression, underscoring its clinical importance.
Zhangrao Huang +5 more
doaj +1 more source
Angewandte Chemie International Edition, EarlyView.1,8‐DHN is an important intermediate to form complex aromatic ring systems. Phenol‐coupling reactions are important for the dimerization of two molecules. Here, we show that a fungal cytochrome P450 enzyme catalyzes specific C─C bonds. ABSTRACT Dihydroxynaphthalene (DHN) derivatives are precursors of biologically important molecules, including melanin ...
Jia Gao +8 more
wiley +1 more source
Rediscovering Psilocybin as an Antidepressive Treatment Strategy
Pharmaceuticals, 2021 There has recently been a renewal of interest in psychedelic research on the use of psilocybin in psychiatric treatment and, in particular, for the treatment of major depressive disorder (MDD).
Rene Zeiss, Maximilian Gahr, Heiko Graf
doaj +1 more source
Exploring new avenues: Psychedelic‐assisted therapy for young people
British Journal of Clinical Pharmacology, EarlyView.Rates of mental illness in young people are increasing, whereas the development of novel mental health treatments has not significantly progressed. Psychedelic‐assisted therapy, using substances such as psilocybin and 3,4‐methylenedioxymethamphetamine (MDMA), has shown potential in the treatment of mental illnesses in the adult population, including ...
Ioanna Artemis Vamvakopoulou +3 more
wiley +1 more source
Cultural and anthropological review of resources
, 2022 prepared by Kirstin Yeomans, Graduate Research Assistant, Oregon Psilocybin Services Section.Title from PDF caption (viewed on July 19, 2022).This archived document is maintained by the State Library of Oregon as part of the Oregon Documents Depository ...
core
Nature CommunicationsPsilocybin increases social connectedness and has strong clinical transdiagnostic efficacy for mental illness, making it a candidate treatment to reduce maternal disconnect, anxiety, and blunted affect seen in peripartum mood disorders.
Cassandra J. Hatzipantelis +15 more
doaj +1 more source
Single-dose psilocybin promotes cell-type-specific changes of neurons in the orbitofrontal cortex
NeurotherapeuticsRecent clinical breakthroughs hold great promise for the application of psilocybin in the treatments of psychological disorders, such as depression, addiction, and obsessive-compulsive disorder.
Ziran Huang +7 more
doaj +1 more source
Will psilocybin lose its magic in the clinical setting?
Therapeutic Advances in Psychopharmacology, 2022 Psilocybin as a novel treatment for depression is garnering a lot of attention from both the mainstream media and the academic community. Although phase 3 trials are only just beginning, we feel that it is important for clinicians to consider what ...
Caroline Hayes +2 more
doaj +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims This study aimed to evaluate the safety, tolerability and pharmacokinetics of a novel oral modified‐release psilocybin formulation (REL‐P11) in normal‐weight and overweight/obese healthy adults and to assess its suitability for controlled, subperceptual exposure, in light of emerging evidence supporting serotonergic modulation in metabolic ...
Anna Signor +11 more
wiley +1 more source